Managing Your Exit

In this era of biotech IPOs, many forget that the data shows that most emerging biotech companies achieve liquidity through an acquisition. But how many of us actually plan for the liquidity result from the very inception of the organization?

An entrepreneur, a seasoned venture capitalist and former entrepreneur, an investment banker, and a representative from pharma speak on the trajectory from cradle to culmination, and what is required to understand the exit scenarios result when drafting the business plan in the garage.

Find out more at the MassBio website >>